A woman in her thirties who was dependent on blood transfusions and unresponsive to every standard treatment for her three ...

CAR-T cell therapy puts woman's three autoimmune diseases into remission after single infusion when nine previous treatments ...

Please provide your email address to receive an email when new articles are posted on . A small percentage of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia ...

Please provide your email address to receive an email when new articles are posted on . Patients with large B-cell lymphoma rarely developed CRS and ICANS more than 2 weeks after CAR T-cell therapy.

The development of the CAR-T technology in the recent years has been a major milestone in the fight against cancer. These sort of “living drugs”, T-cells modified to expanse, recognize and attack ...

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, ...

The findings are notable because thrombotic complications are often emphasized in cancer care, yet this analysis found that ...